title: Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.
abstract: Neurotoxicity developed in 22 of 97 children and adolescents with malignant solid tumors treated within a phase II ifosfamide protocol. The occurrence of neurotoxicity was related to previous cumulative dosages of cisplatin. One third of the patients who had received more than 600 mg/m2 of cisplatin developed this complication. The relative risk increased 3.2-fold with previous cisplatin dosages above 301 to 600 mg/m2, and 4.1-fold with dosages of 601 to 1,340 mg/m2. The increased risk of neurotoxicity in patients who had received more than 600 mg/m2 of cisplatin may be related to either a decreased clearance of ifosfamide itself or of the drug's active metabolites.
authors.affiliation: Departments of Hematology-Oncology, St Jude Children's Research Hospital, Memphis, TN 38101-0318.
authors.forename: C B
authors.initials: CB
authors.lastname: Pratt
authors.forename: M P
authors.initials: MP
authors.lastname: Goren
authors.forename: W H
authors.initials: WH
authors.lastname: Meyer
authors.forename: B
authors.initials: B
authors.lastname: Singh
authors.forename: R K
authors.initials: RK
authors.lastname: Dodge
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects*; D009369:Neoplasms / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000139:chemically induced*; D012306:Risk
chemical_list: D002945:Cisplatin; D007069:Ifosfamide